Polio endgame management: Focusing on performance with or without inactivated poliovirus vaccine

The Lancet

Volumn 384, Issue 9953, 2014, Pages 1480-1482

  Thompson, Kimberly M ^a  

^a UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INACTIVATED POLIOVIRUS VACCINE; INACTIVATED VIRUS VACCINE; POLIOMYELITIS VACCINE; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; COST EFFECTIVENESS ANALYSIS; HEALTH CARE POLICY; HUMAN; IMMUNIZATION; MUCOSAL IMMUNITY; NOTE; PARALYSIS; POLIOMYELITIS; POLIOMYELITIS VIRUS 1; SEROCONVERSION; SEROTYPE; VIRUS IMMUNITY; VIRUS TRANSMISSION; FEMALE; MALE;

FEMALE; HUMANS; MALE; POLIOMYELITIS; POLIOVIRUS VACCINE, INACTIVATED;

EID: 84908321273     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)60983-1     Document Type: Note

References (13)

1. J John, S Giri, AS Karthikeyan et al. Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: an open-label, randomised controlled trial Lancet 2014 published online July 11. http://dx.doi.org/10.1016/S0140-6736(14)60934-X
2. CF Estívariz, H Jafari, RW Sutter et al. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6-9 months in Moradabad, India: a community-based, randomised controlled trial Lancet Infect Dis 12 2012 128 135
3. KM Thompson, RJ Duintjer Tebbens National choices related to inactivated poliovirus vaccine, innovation, and the end game of global polio eradication Exp Rev Vaccines 13 2014 221 234
4. The Global Polio Eradication Initiative A year without type 3: could type 1 be the only wild polio serotype left in the world? http://www.Polioeradication.Org/mediaroom/newsstories/newsstories2013/tabid/488/iid/336/default.Aspx#sthash.Kwton8xj.Dpuf Nov 13, 2013 (accessed June 26, 2014).
5. Independent Monitoring Board of the Global Polio Eradication Initiative Ninth report - May, 2014 http://www.polioeradication.org/Portals/0/Document/Aboutus/Governance/IMB/10IMBMeeting/10IMB-Report-EN.pdf (accessed June 18, 2014).
6. KM Thompson, MA Pallansch, RJ Duintjer Tebbens, SG Wassilak, J-H Kim, SL Cochi Pre-eradication vaccine policy options for poliovirus infection and disease control Risk Anal 33 2013 516 543
7. E Anis, E Kopel, S Singer et al. Insidious reintroduction of wild poliovirus into Israel, 2013 Euro Surveill 18 2013 20586
8. WHO Detection of poliovirus in sewage, Brazil http://www.who.int/csr/don/2014-6-23polio/en/ June 23, 2014 (accessed July 8, 2014).
9. KM Thompson, MA Pallansch, RJ Duintjer Tebbens, SGF Wassilak, SL Cochi Modeling population immunity to support efforts to end the transmission of live polioviruses Risk Anal 33 2013 647 663
10. RJ Duintjer Tebbens, MA Pallansch, DA Kalkowska, SG Wassilak, SL Cochi, KM Thompson Characterizing poliovirus transmission and evolution: insights from modeling experiences with wild and vaccine-related polioviruses Risk Anal 23 2013 703 749
11. RJ Duintjer Tebbens, MA Pallansch, KM Chumakov et al. Expert review on poliovirus immunity and transmission Risk Anal 33 2013 544 605
12. DA Kalkowska, RJ Duintjer Tebbens, KM Thompson Modeling strategies to increase population immunity and prevent poliovirus transmission in two high-risk areas in northern India J Infect Dis 2014 (in press).
13. RJ Duintjer Tebbens, KM Thompson Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation J Infect Dis 2014 (in press).